Tabuk Launches Vibativ Antibiotic in Saudi Arabia to Combat Multidrug-Resistant Infections
Key Insights
Tabuk Pharmaceutical Manufacturing Company (search) has launched Vibativ (telavancin) injection in Saudi Arabia through an exclusive partnership with Cumberland Pharmaceuticals, targeting hospital-acquired pneumonia (search) and serious skin infections.
The FDA-approved antibiotic is specifically designed to combat multidrug-resistant Gram-positive bacteria, including MRSA (search) and MSSA (search), with studies showing it maintains potency against resistant strains over 10 years after introduction.
Vibativ demonstrated significantly higher cure rates compared to vancomycin in clinical trials for hospital-acquired and ventilator-associated bacterial pneumonia, offering once-daily dosing without therapeutic drug monitoring requirements.
Tabuk Pharmaceutical Manufacturing Company (search) and Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced the launch of Vibativ® (telavancin) injection in Saudi Arabia on September 29, 2025, marking a significant expansion of access to this FDA-approved antibiotic designed to combat multidrug-resistant bacterial infections.
The partnership grants Tabuk exclusive rights to register and promote Vibativ for patients in Saudi Arabia and other Middle Eastern countries, addressing the growing threat of antimicrobial resistance in the region.
Targeting Critical Resistant Infections
Vibativ is a patented, injectable anti-infective that serves as a potentially life-saving treatment for patients with hospital-acquired and ventilator-associated pneumonia (search), including infections resulting from influenza and COVID-19. The antibiotic is specifically designed to treat serious infections caused by Staphylococcus aureus and other Gram-positive bacteria, including both Methicillin-resistant Staphylococcus aureus (MRSA (search)) and Methicillin-sensitive Staphylococcus aureus (MSSA (search)).
"Given the global concern about multidrug-resistant organisms, Vibativ is an important addition to our anti-infective portfolio and supports our mission to deliver unique health solutions and save the lives of people throughout the Middle Eastern countries we operate in," said Ismail Shehadah, CEO of Tabuk.
Superior Clinical Performance
The antibiotic has demonstrated superior efficacy in large, multinational registrational studies involving one of the largest cohorts of patients with S. aureus infections studied to date. These trials showed significantly higher cure rates for Vibativ compared to vancomycin in hospital-acquired and ventilator-associated bacterial pneumonia caused by any single Gram-positive pathogen or S. aureus with vancomycin minimum inhibitory concentration ≥1 μg/mL.
Vibativ offers practical advantages for healthcare providers, including once-daily intravenous dosing without the need for therapeutic drug monitoring, which decreases healthcare professionals' exposure to patients. The drug exhibits bactericidal activity within six hours and demonstrates effective penetration into target infection sites.
Innovative Mechanism Against Resistance
Unlike many recently introduced antibiotics that quickly lose effectiveness as bacteria develop resistance, Vibativ was specifically engineered to combat drug-resistant bacteria. The antibiotic is based on vancomycin but incorporates both lipophilic and hydrophilic components. The lipophilic addition enhances Vibativ's ability to penetrate bacterial cell walls and inhibits the formation of new cell walls, while the hydrophilic component increases tissue penetration, enabling the drug to attack infections unreachable by other antibiotics.
Studies demonstrate that Vibativ maintains the same potency against difficult-to-treat and multidrug-resistant bacteria today as when it was introduced over 10 years ago, highlighting its sustained effectiveness against evolving bacterial resistance.
Addressing Global Health Crisis
According to the World Health Organization, antimicrobial resistance represents an urgent global health and socioeconomic crisis. The global rise in antibiotic resistance poses a significant threat, diminishing the efficacy of many common antibiotics against widespread bacterial infections.
"We are very pleased to expand the reach of Vibativ – an important and potentially life-saving drug – through this partnership with Tabuk," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "We are confident that Tabuk has the resources and experience to ensure Vibativ reaches as many patients in Saudi Arabia as possible."
Approved Indications and Market Reach
Vibativ is approved in both the United States and Saudi Arabia for treating adult patients with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible S. aureus isolates when alternative treatments are not suitable. The drug is also approved for complicated skin and skin structure infections (search) caused by susceptible Gram-positive bacteria, including both MSSA (search) and MRSA (search) strains.
Tabuk Pharmaceutical Manufacturing Company (search) operates as a leading pharmaceutical company in the Middle East and North Africa, with four state-of-the-art manufacturing sites and a workforce of more than 2,400 employees. The company currently reaches patients in 17 countries across the Middle East and Africa, with plans for further regional expansion.